Background: Anaplastic lymphoma receptor tyrosine kinase gene (ALK) fusion is a distinct molecular subclassification of NSCLC that is targeted by anaplastic lymphoma kinase (ALK) inhibitors. We established a transgenic mouse model that expresses tumors highly resembling human NSCLC harboring echinoderm microtubule associated protein like 4 gene (EML)-ALK fusion. We aimed to test an EML4-ALK transgenic mouse model as a platform for assessing the efficacy of ALK inhibitors and examining mechanisms of acquired resistance to ALK inhibitors.
Introduction
NSCLC is the leading cause of death by cancer worldwide. 1 Adenocarcinoma is the most common form of NSCLC. NSCLC is further categorized by distinct molecular subclassifications harboring specific genetic alterations. [2] [3] [4] Echinoderm microtubule associated protein like 4 (EML4)-anaplastic lymphoma receptor tyrosine kinase gene (ALK) fusion accounts for 4% to 8% of NSCLC, 5 and tumors with oncogenic ALK rearrangements are exquisitely sensitive to anaplastic lymphoma kinase (ALK) blockade with tyrosine kinase inhibitors (TKIs).
Crizotinib, the first U.S. Food and Drug Administrationapproved ALK TKI, has shown remarkable efficacy in patients with advanced NSCLC who are harboring EML4-ALK fusion gene. For first-line treatment with crizotinib, progression-free survival is 10.9 months and the overall response rate (ORR) is 74%. 6 For second-line treatment with crizotinib, progression-free survival is 7.7 months and the ORR is 65%. 7 Within 1 year of treatment, however, ALK-positive tumors eventually develop acquired resistance to ALK TKIs that is manifested by disease progression and leads to a dismal prognosis. 8 Previous studies on the mechanisms of resistance have shown that the secondary mutations in the ALK kinase domain result in insensitivity to crizotinib. 9 Approximately 30% of crizotinib-refractory tumors harbor resistance mutations in the ALK kinase domain, including L1196M, C1156Y, F1174Y, and G1202R. Recently, the second-generation ALK TKIs ceritinib and alectinib have been approved for use in patients with crizotinib-refractory NSCLC. 10 Although both inhibitors show efficacy in these settings, resistance to both In a wild-type (WT) mouse, echinoderm microtubule associated protein like 4 (EML4)-intron F primer binds on mouse intron 1, and EML4-R common primer binds on both human and mouse high homologous EML4 exon 2 region (the product size is 632 base pairs [bp]). In transgenic mouse, pCB-F primer binds (pCB vector region), and EML4-R-common primer can produce 279-bp polymerase chain reaction products. (B) Genotypes of EML4-ALK transgenic mice were confirmed by polymerase chain reaction. WT allele shows a 632-bp band, whereas the transgenic allele shows a 279-bp band. The copy number of EML4-ALK transgene plasmid was serially diluted with WT genomic DNA (0-1000 copies). Two positive transgenic mice (mice 3 and 4) and two WT mice (mice 1 and 2) are seen. CMV, cytomegalovirus; PGK, phosphoglycerate kinase.
these inhibitors has also emerged 11 Relapsed tumors after ceritinib and alectinib therapy often express the ALK G1202R mutation, which emphasizes that G1202R mutation confers a high level of resistance in both first-and second-generation ALK inhibitors. ALK G1202R is postulated to be on the solvent-exposed region of the ALK kinase domain abutting the binding site and diminishing the binding affinity of ALK inhibitors to the mutant ALK from steric hindrance owing to a large basic residue. 12 Besides these secondary mutations, activated bypass signaling pathways (EGFR, KRAS, Kit proto-oncogene receptor tyrosine kinase, mesenchymal-epithelial transition, and insulin-like 1 growth factor receptor) that allow continuous cell proliferation and survival may also induce resistance. [12] [13] [14] Therefore, identification of underlying mechanisms of drug resistance is essential in the course of the disease, and other unknown mechanisms of resistance still need to be elucidated. However, it is often not easy to identify mechanisms of resistance in patients because of lack of tissue for analysis or difficulty in performing invasive procedures for tumor biopsy.
Recently, preclinical genetically engineered murine cancer models (GEMMs) have enabled recapitulation of human NSCLC. 15, 16 Previous works include generation by Ji et al. of bitransgenic mice with inducible expression in type II pneumocytes of two common human EGFR mutants seen in human lung cancer. Human EGFR mutations were not only oncogenic in vivo, but their expression was also essential for tumor survival and maintenance. 17 Li et al. generated a doxycyclineinducible mouse model harboring EGFR T790M mutation (the most common acquired resistant mutation to EGFR TKIs) that showed resistance to erlotinib in vivo. 18 GEMMs allow murine clinical trials that can predict the outcome of clinical trials and accelerate more effective oncologic drug development. 19 In addition, it is easier to identify mechanisms of resistance in murine models than in real patients, which may facilitate discovery of rational combinatorial strategies that can be implemented in human clinical studies.
In the present study, we have developed a conditional transgenic mouse model for expressing human EML4-ALK fusion gene under the control of surfactant protein C (SPC)-Cre-estrogen receptor T2 (Cre-ERT2) through tamoxifen treatment to evaluate the efficacy of ALK inhibitors and to discover mechanisms of acquired resistance. We were able to observe regrowth of tumors that exactly mimics human conditions after development of acquired resistance and identify the ALK G1202R mutation in resistant tumors. This murine model will be very useful to explore the best treatment strategy using ALK TKIs to expand their roles in the growing ALK armamentarium. In particular, development of next-generation ALK TKIs that can overcome a high level of acquired resistance such as ALK G1202R mutation may be accomplished.
Materials and Methods

Ethics of Animal Experiments
This study's compliance with worldwide standard animal care conditions was ensured by an institutional animal care and use committee. The research proposal was approved by Yonsei University Institutional Animal Care and Use Committee (2014-0249). All experimental mice were housed in colony cages and maintained on a cycle of 12 hours of light and 12 hours of dark in an Association for Assessment and Accreditation of Laboratory Animal Care International-certified specific pathogen-free facility.
SPC-Cre-ERT2 Knockin Mice
The Cre mouse line expressing Cre-ERT2 from the mouse surfactant protein C gene (SPC) gene locus (SPC-Cre-ERT2 mice) was kindly provided by Dr. Harold 
Conditional EML4-ALK Transgenic Mice
LoxP-STOP-LoxP sequence from pBigT, terminating transcription 20 was subcloned into the EcoRI site of a pCAGGS vector, 21 and cDNA fragment encoding FLAGStagged EML4-ALK fusion protein was subsequently ligated using the NotI site. The inserted EML4-ALK gene is a variant type 1 that originated from Homo sapiens.
After confirmation of transgene expression in HEK293T cells by Western blot analysis, the purified linearized transgene construct was microinjected into pronuclear-stage mouse embryos (C57BL/6N) and transferred to pseudopregnant mice. Two transgenic founder mice harboring EML4/ALK fusion gene were identified by polymerase chain reaction (PCR) amplification of tail genomic DNAs and established through germline transmission.
Genotypes of EML4-ALK transgenic mice were confirmed by PCR with the following three primers. pCB-F: 5 0 -TGT CTG GAT CCC CAT CAA GC-3 0 , mEML4-intron-F: 5 0 -TTA CCT GCT GTG CCA TCC TG-3 0 , and EML4-R_common: 5 0 -GAA CTC GTG ACT CAA GAG CTG-3 0 . Genomic DNAs were extracted from tails or toes of mice using Qiaprep Tail DNeasy isolation kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. Ten nanograms of genomic DNA and 10 pmol of primers were used for PCR. The PCR conditions were as follows: 5 minutes of denaturation at 95 C; 40 seconds at 95 C, 30 seconds at 58 C, and 30 seconds at 72 C for cycle condition; and 5 minutes at 72 C for termination.
Production of SPC-Cre-ERT2/EML4-ALK Transgenic Mice
Mating of SPC-Cre-ERT2 knockin mice and EML4-ALK transgenic mice was performed to generate SPC-Cre-ERT2/EML4-ALK transgenic mice. The transgenic mice were given tamoxifen at days 3 and 6 by intraperitoneal injection. The estrogen receptor ligand activated Cre-ERT2 to express EML4-ALK gene in the lungs.
Western Blot
Five-week-old SPC-Cre-ERT2/EML4-ALK transgenic mice were humanely killed for tissue sample collection. Lung, heart, liver, stomach, kidney, colon, and brain tissue samples were collected. Protein lysates were prepared using protein extraction buffer (Cell Signaling Technology, Danvers, MA). The lysates were loaded on 6% sodium dodecyl sulfate polyacrylamide gel electrophoresis for Western blotting. The transferred nitrocellulose membrane was blocked with 3% bovine serum albumin for 30 minutes. Then, the membrane was incubated with anti- Numerous tumor nodules were observed in both lungs of EML4-ALK mice. (B) On hematoxylin and eosin (H&E) stain, the normal alveolar epithelia were shown, and after tamoxifen treatment, development of acinar or papillary type of lung adenocarcinoma was seen (C). WT, wild type.
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human ALK-rabbit immunoglobulin G (Cell Signaling Technology). Anti-rabbit immunoglobulin G-horseradish peroxidase-conjugated antibody was used as a secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA).
Tumorigenesis and Magnetic Resonance Imaging
For tumorigenesis, treatment of tamoxifen is needed for activation of Cre-ERT2. Tamoxifen (4-OHT) (Sigma Chemical, St. Louis, MO) was dissolved in 100% ethyl alcohol to a 10 mg/mL solution by vortexing and incubation at 37 C. To prepare for injection, we added 25 mL of 10 mg/mL tamoxifen to 100 mL corn oil and then vacuum-centrifuged it for 2 hours. Next, 0.25 mg of tamoxifen was injected intraperitoneally regardless of mouse sex or weight. The injection was performed twice at a 3-day interval (Monday and Thursday). EML4-ALK lung tumors developed in 13 mice. Tumors were observed after 1 week by magnetic resonance imaging (MRI). For MRI, the mice were anesthetized with isoflurane in 100% oxygen. To minimize motion effects, respiratory gating was performed, and the magnetic resonance signal was synchronized with the respiratory cycles. MRI protocols were optimized for assessing pulmonary parenchyma at 9.4 T (BioSpec 94/20 USR MRI system [Bruker, Billerica, MA]). Tumors were analyzed by T2-weighted image.
Immunohistochemistry
EML4-ALK transgenic mice were treated with tamoxifen as described earlier and then humanely killed with a lethal dose of CO 2 per institutional guidelines. The lungs were excised; the left lung was fresh-frozen in liquid nitrogen for molecular analyses, and the right lung was fixed with 10% neutral formaldehyde. All lungs were sectioned in the same fashion, and 4-to 5-mm-thick tissue samples were cut and attached on coating slides. For immunohistochemistry, paraffin-embedded sections of the lung were deparaffinized, rehydrated, incubated with a serum blocking solution, and incubated with the primary anti-ALK and anti-FLAGS antibodies diluted in bovine serum albumin at 4 C overnight. After incubation with the primary antibodies, the slides were stained using an anti-rabbit ABC staining kit (Santa Cruz Biotechnology) according to the Avidin biotin system (ThermoFisher Scientific, USA). Counterstaining was performed with Mayer's hematoxylin solution. The EML4-ALK tumor (brown) was visualized by horseradish peroxidase substrate.
ALK TKI Treatment in Transgenic Mice
After tumor formation was confirmed by MRI (T2-weighted image), mice were treated with 150 mg/kg of crizotinib orally once daily. MRI was performed every 2 weeks to monitor the antitumor effect of crizotinib until progressive disease (PD). PD was defined as at least a 20% increase in tumor burden from the baseline. Partial response was defined as at least a 30% decrease in tumor burden from baseline. Tumor burden changes between -30% and þ20% were defined as stable disease. Complete response was defined as disappearance of all tumors. Acquired resistance to crizotinib developed in three of 13 mice.
Statistical Analysis
Variance for all group data is expressed as plus or minus the SD.
Results
Establishment of a Conditional Transgenic Mouse Model for Lung-Specific EML4-ALK Expression
Genotyping of EML4-ALK transgenic mice was performed using two primers targeting tpA and EML4-ALK (exon 2) (Fig. 1A) . Two positive transgenic mice (founders 3 and 4) and two wild type mice (mice 1 and 2) were seen (Fig. 1B) . Transgenic mice 3 and 4 appeared to possess approximately 100 copies of the transgene. The established EML4-ALK transgenic mouse was mouse 4. Founder 4 recapitulated lung adenocarcinoma pathologically.
To conditionally express EML4-ALK transgene, we constructed the transgene depicted in Figure 2 . Although a strong CAG promoter was used, 21 the LoxP-STOP-LoxP can efficiently block the expression of EML4-ALK transgene. 20 The transgenic mouse model with highly During the first week, tamoxifen injection was performed on days 3 and 6. After 2 weeks, magnetic resonance imaging (MRI) was performed to examine lung tumorigenesis. Then, crizotinib (200 mg/kg) was administered daily, and its efficacy was monitored by MRI every 2 weeks. MRI was followed up until progressive disease (PD) was observed. (B) MRI scan of SPC-Cre-ERT2/EML4-ALK transgenic mice exhibited multiple tumor nodules after treatment with tamoxifen. After 2 weeks of treatment with crizotinib (150 mg/kg), lung tumor nodules showed complete response (CR) in two mice and partial response (PR) in one mouse. After 4 weeks of treatment, PD was observed in the form of numerous nodules throughout both lungs in all three mice. (C) On hematoxylin and eosin stain, tumor nodules were selected with laser microdissection and sequenced for ALK kinase domain mutation from M876 and M869. (D) Development of secondary mutation in the ALK kinase domain was checked with Sanger sequencing. (E) A gatekeeper mutation G1202R was identified from resistant tumor nodules in M876. ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitor.
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Mouse Model of EML4-ALK-Positive NSCLClung-specific, inducible expression of EML4-ALK fusion protein was established by crossing the EML4-ALK transgenic mice with mice expressing tamoxifeninducible recombinase Cre-ERT2 fusion protein under the control of SPC. Even though Cre-ERT2 is expressed in lung tissue, it cannot induce the expression of EML4-ALK without the tamoxifen treatment. When the transgene was transfected into HEK293T cells, FLAGS-EML4-ALK protein was not detected. Upon the cotransfection of Cre-expressing construct, FLAGS-EML4-ALK transgene was strongly induced (Fig. 3A) . This result indicates that the transgene expression was completely dependent on Cre expression. To confirm lung-specific expression of EML4-ALK transgene, we performed Western blot analysis to detect EML4-ALK in the lung, brain, kidney, stomach, colon, and liver of EML4-ALK-transgenic F1 mice. EML4-ALK protein was detected at 120 KDa (variant type 1) only in the lung, which supports the role of SPC promoter in tissue-specific expression (Fig. 3B ).
FLAGS-EML4-ALK Expression Induces Lung Tumors in Transgenic Mice
Gross tumor morphologic structure was observed after 1 week of tamoxifen treatment in EML4-ALK mice and compared with that in mice not treated with tamoxifen (Fig. 4A) . Tumor nodules were observed in both of lung lobes in EML4-ALK mice. Upon hematoxylin and eosin staining, the acinar or papillary type of adenocarcinoma was observed in both low-and high-power fields (Fig. 4B  and C) , and cytoplasmic staining of ALK and FLAGS was seen (Fig. 4C) . Because EML4-ALK protein carries the FLAGS epitope on the N-terminal, the expression of both ALK and FLAGS were observed in the same region.
EML4-ALK Transgenic Mice as a Platform for Evaluating Efficacy of ALK TKIs
SPC-Cre-ERT2/EML4-ALK transgenic mice were treated with crizotinib. Crizotinib, 150 mg/kg, was orally administered daily until PD, and MRI was performed every 2 weeks (Fig. 5A) . No mice showed signs of crizotinib toxicity in terms of body weight. The pretreatment MRI scan showed multiple hematogenous lung nodules in both lung lobes. After 2 weeks of crizotinib treatment, complete response of tumor was seen. However, continuous treatment with crizotinib led to regrowth of lung tumor nodules after 4 weeks, showing acquired resistance to crizotinib (Fig. 5B) . To identify the mechanisms of resistance, we dissected each tumor nodule from two mice (M876 and M869) and sequenced the kinase domain of the ALK gene (Fig. 5C and D) . From the three resistant tumor nodules in mouse M876, we identified ALK G1202R gatekeeper mutations in two nodules (Fig. 5E and Supplementary Fig. 1 ). The remaining two nodules did not harbor any known ALK mutations (Table 1) .
Discussion
In this study, we have demonstrated that EML4-ALK transgenic mice are recapitulative of human EML4-ALK tumor and can be used as a testing platform for ALK TKIs. In our model, EML4-ALK lung cancer developed within a short period (within 1 week) after treatment with tamoxifen and was confirmed by MRI and histological and molecular analyses. Similar to human NSCLC, the tumor responded dramatically to crizotinib, but acquired resistance then developed after 12 to 14 weeks. Importantly, the identification of resistance mechanism (ALK G1202R mutation) from ALK inhibitor treatment suggests that our model can aid in development of nextgeneration ALK inhibitors. The underlying resistance mechanism (G1202R) identified in our model will enable us to develop strategies to overcome resistance or delay the onset of resistance.
Although wide use of next-generation sequencing has resulted in development of numerous target-specific small molecule inhibitors and antibodies in the treatment of lung cancer, ensuring the safety and efficacy of a new inhibitor in clinical trials takes years. Additionally, acquired resistance to these inhibitors invariably occurs in patients who initially responded to treatment. Thus, it is important to develop GEMMs that recapitulate human NSCLC, which can lead to successful prediction of clinical outcomes and efficacy of novel treatment strategies. Implementation of coclinical trials using this well-defined murine EML4-ALK lung cancer model will facilitate drug development through evaluation of treatments.
Currently available transgenic lung cancer models include CCSP-rtTA-KRASG12V-TetO and SPC-rtTA/(TetO) 7-KrasG12D mice, which are generated with doxycycline treatment. 22 However, doxycycline-mediated transgenic mice have a few limitations. First of all, long exposure to doxycycline is necessary for tumorigenesis. The mice maintained on doxycycline-containing food or drinking water until they are killed and the timing of doxycycline exposure may influence the sites and extent of gene activation or deletion. 23 Second, antibiotic effects of doxycycline may influence intestinal microflora, which is an important element of drug metabolism and tumor microenvironment. 24 In addition, the toxicity of doxycycline may have a confounding impact on the phenotype of a transgenic mouse, including impaired alveologenesis, loss or reduction of surfactant-association proteins, and even death. 25 Our model has demonstrated that assessing drug efficacy is feasible within a month. This provides a strong preclinical model for rapidly evaluating next-generation ALK inhibitors in upfront or later-line settings. Indeed, there are large-scale clinical trials that examine the efficacy of next-generation ALK inhibitors in both crizotinib-naive and crizotinib-resistant populations. Our results here provide a useful basis for further investigations of next-generation ALK inhibitors that can overcome resistance in vivo. Recently, Ota et al. reported that EML4-ALK oncogene induces the expression of PD-L1. 26 This provides insight that combination of antiprogrammed cell death 1/programmed death-ligand 1 therapy and an ALK inhibitor may be more efficacious than an ALK inhibitor alone. Our model will serve as a powerful experimental tool for evaluating these immunooncologic drugs by evaluating efficacy and toxicity and their associated predictive biomarkers. Finally, clinical trials using GEMM models will ultimately help prioritize novel drug treatments and guide the development of future clinical trial designs.
